The first quarter of 2026 has shattered all previous records for venture capital investment, with a staggering $297 billion poured into startups worldwide. This colossal figure represents a 150 percent increase both quarter-over-quarter and year-over-year, according to a Crunchbase report cited by Trending Topics. The overwhelming driver of this surge is artificial intelligence, which has captured a remarkable 81 percent of all global VC investment, amassing $239 billion. This dwarfs the 55 percent share AI held in the previous record quarter of Q1 2025.
Four of the five largest venture capital rounds in history occurred in Q1 2026. Notably, OpenAI secured a monumental $122 billion, followed by Anthropic with $30 billion, xAI with $20 billion, and Waymo with $16 billion, collectively accounting for $186 billion of the total investment. This concentration of capital in a few mega-rounds has significantly boosted valuations, adding $900 billion to the Crunchbase Unicorn Board in a single quarter.
This trend is not confined to a few dominant players. Ten other companies also closed rounds exceeding $1 billion, spanning sectors such as autonomous vehicles, semiconductors, robotics, and defense. The United States continues to lead in VC investment, attracting $247 billion, or 83 percent of the global total in Q1 2026. China and the United Kingdom followed, with $16.1 billion and $7.4 billion respectively.
Meanwhile, in a significant development for AI research, Professor David Silver, the computer scientist behind AlphaGo, has raised $1.1 billion in seed funding for his new venture, Ineffable Intelligence. The company aims to develop AI systems that learn from experience rather than solely from human-generated data, marking a substantial investment in a new frontier of AI development. This funding round is noted as one of the largest seed rounds in European history.
Another notable funding announcement comes from German biotech startup Primogene, which has raised €4.1 million ($4.8 million) to commercialize its enzymatic breast milk biomolecules for infant formula and other nutritional products. The company utilizes a biocatalysis platform to reproduce complex molecules identical to their natural counterparts, with a focus on human milk oligosaccharides. This investment highlights the growing interest in specialized biotech solutions within the broader health and wellness sector.